Physician profile
Vikram Malladi
NPI 1902814015
$5,784.95
in general payments reported to CMS, 2019-2025
29 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $629 · 2021: $913 · 2022: $1,089 · 2023: $580 · 2024: $592 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953 · Education: $28.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.76 |
| Education | $28.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,853.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $963.15 | 2019-2024 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $610.68 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $528.98 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $272.82 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $264.78 | 2020-2022 | |
| Pfizer INC. | $231.10 | 2019-2025 | |
| Boston Scientific Corporation | $121.62 | 2019 | |
| Nestle Healthcare Nutrition INC. | $100.27 | 2022-2023 | |
| Madrigal Pharmaceuticals | $88.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $81.90 | 2024-2025 | Iqirvo, Bylvay |
| Braintree Laboratories, INC. | $70.65 | 2019-2025 | Sutab |
| Phathom Pharmaceuticals, INC. | $64.47 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $61.68 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $57.41 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51.21 | 2023-2025 | Dupixent |
| Redhill Biopharma INC. | $45.58 | 2020-2022 | |
| Allergan, INC. | $45.21 | 2019-2020 | |
| Shionogi INC | $32.63 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $28.87 | 2020 | |
| Aimmune Therapeutics, INC. | $28.18 | 2025 | Zenpep |
| Celltrion USA INC. | $28.14 | 2023 | Yuflyma |
| Ardelyx, INC. | $27.59 | 2025 | Ibsrela |
| Novo Nordisk INC | $27.47 | 2025 | Wegovy |
| Qol Medical, LLC | $23.27 | 2024 | Sucraid |
| Organon LLC | $21.81 | 2024 | |
| Genzyme Corporation | $21.50 | 2022 | |
| Celgene Corporation | $16.02 | 2021 | |
| Daiichi Sankyo INC. | $15.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Malladi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.